Cigarette smoking is associated with an increased risk of leukemia; beniene, an established leukemogen, is present in cigarette smoke. By combining epidemiologic data on the health effects of smoking with risk assessment techniques for low-dose exrapolation, we assessed the proportion of smoking-induced total leukemia and acute myeloid leukemia (AML) attributable to the benzene in cigarette smoke. We fit both linear and quadratic models to data from two benzene-exposed occupational cohorts to estimate the leukemogenic potency of benzene. Using multiple-decrement life tables, we calculated lifetime risks of total leukemia and AML deaths for never, light, and heavy smokers. We repeated these calculations, removing the effict of benzene in cigarettes based on the estimated potencies. From these life tables we determined smoking-attributable risks and benzeneattributable risks. The ratio of the latter to the former constitutes the proportion of smokinginduced cases attributable to benzene. Based on linear potency models, the benzene in cigarette smoke contributed from 8 to 48% of smoking-induced total leukemia deaths [95% upper confidence limit (UCL), 20-66%], and from 12 to 58% of smoking-induced AML deaths (95% UCL, 19-121%). The indCusion of a quadratic term yielded results that were comparable; however, potency models with only quadratic terms resulted in much lower attibutable fractions-all c 1%. Thus, benzene is estmated to be responsible for approximately one-tenth to one-half of smokinginduced totl leukenmia mortality and up to three-fifths of smoking-related AML mortality. In contrast to theoretical arguments that linear models substantially overestimate low-dose risk, linear extrapolations from empirical data over a dose range of 10-to 100-fold resulted in plausible predictions.
potency models with only quadratic terms resulted in much lower attibutable fractions-all c 1%. Thus, benzene is estmated to be responsible for approximately one-tenth to one-half of smokinginduced totl leukenmia mortality and up to three-fifths of smoking-related AML mortality. In contrast to theoretical arguments that linear models substantially overestimate low-dose risk, linear extrapolations from empirical data over a dose range of 10- Benzene is present in mainstream cigarette smoke at concentrations of approximately 45 pg/cigarette, and in sidestream smoke at concentrations about 10 times higher. Personal exposure assessment research has indicated that the average cigarette smoker inhales 6-10 times the benzene inhaled by the average nonsmoker, and that approximately 90% of a smoker's benzene exposure is from smoking (4) . For nonsmokers, most benzene exposure comes from automobile exhaust, environmental tobacco smoke, and exposure to consumer products (5) . Benzene induces leukemia both in humans with occupational exposures (6, 7) and in experimental animals (8, 9) . Some research indicates the strongest association of benzene to be with acute myeloid leukemia (AML) (10, 11) , but effects on other types of leukemia have not been ruled out (12) . The purpose of this investigation was to determine what proportion of smoking-induced leukemia is likely to be caused by the benzene in cigarette smoke.
Several regulatory agencies, including the U.S. Environmental Protection Agency (EPA), have established procedures for estimating risks from low-or moderate-level chemical exposures (13) . These risk assessment methods, which assume low-dose linearity, have been used for over a decade to set regulatory standards, and we used these methods to calculate leukemia risks from benzene in cigarette smoke. The EPA has proposed new guidelines for risk assessment (14) , which are still under debate. Our use of the earlier standard permitted an assessment of its adequacy for benzene. Some authors have argued that the true low-dose relationship for this compound is sublinear, and that the default assumptions will therefore result in a substantial overestimation of benzene's potency (15) . This investigation was specifically designed to quantitatively test whether these assumptions do, in fact, result in the prediction of more leukemia deaths than actually occur in smokers.
In general, risk assessment uses quantitative dose-response data that associate a chemical exposure with the risk of cancer mortality to obtain a potency, and low-dose extrapolation models to estimate the risk at lower doses. Often the dose levels of interest are experienced through environmental exposure in the general population or through occupational exposure in groups of workers. In this case, we examined the benzene doses inhaled by smokers. Unlike many exposure scenarios, the risks to smokers have been well characterized. Thus, the predicted leukemia risks attributable to low-doses of benzene can be compared with the actual leukemia risk observed in epidemiologic studies of smoking.
Materials and Methods
We used five steps to estimate the proportion of smoking-induced leukemia caused by benzene in cigarette smoke: a) a calculation of the lifetime risk of leukemia due to smoking; b) a determination of the leukemogenic potency of benzene; c) the quantification of benzene dose for smokers at two levels of smoking; a) the characterization of the lowdose risk of leukemia due to the benzene in cigarette smoke [using the results of b) and c)]; and e) a comparison of the predicted lifetime leukemia risk due to benzene in cigarette smoke [ (27) by extending mortality data to the most recent follow-up (28) , and by expanding the analyses to indude an exposure matrix developed by Paustenbach et al. (29) . Crump (22) is a simplified version of the fundamental relation between observed and expected rates; Equation 1 is obtained by multiplying both sides of this relation by the personyears in the denominators of both rates. As is standard practice for quantitative risk assessment, we calculated a 95% upper confidence limit (UCL) for each potency.
For the China data, we fit a linear model without the a term because the analysis was based on an internal comparison: obs= exp(l + x a). [2] Because the Pliofilm data suggest a nonlinear dose-response curve, we repeated the Pliofilm analysis using two quadratic multiplicative models: obs=axexp(l +,Pxd2) [3] obs=axexp(l+plxd+P2xd2). [4] It is more difficult to choose an estimate of the amount of benzene in sidestream smoke because measurement methods are not standardized. Given the uncertainty, we chose 500 pg/cigarette, the mid point of the range (300-700 pg/cigarette) reported by Guerin et al. (33) .
We assumed that 100% of the benzene in mainstream smoke is inhaled. We searched the literature but were unable to find direct data on the proportion of sidestream smoke inhaled by a smoker. We therefore used data on the proportion of nicotine inhaled from sidestream smoke. We calculated that if each cigarette requires 10 min to smoke and generates an environmental nicotine concentration of 1,000 pg/m3 for the smoker [the maximum reported by the National Research Council (34)], then that smoker breathes, at most, 100 pg sidestream nicotine from each cigarette: x d2 for models with both a linear and a second-order term. In this way, using the inverse of our dose-response models, we obtained the expected death rates and cumulative lifetime risk for a population of smokers unexposed to benzene.
Bene-attributablefraction ofsmokinginduced leukemia deaths. The proportion of smoking-induced leukemia deaths due to the benzene in cigarette smoke is denoted the ben- Table 3 .
The benzene-associated risks among smokers for AML alone are shown in Table  4 . The AML potencies ranged from 2.0 x 10-3 to 3.4 x 10-3 per cumulative gram benzene for the linear models (95% UCL, 3.4 x 10-3 to 8.2 x 10-3). Using maximum likelihood estimates for the linear models, the proportion of smoking-induced AML deaths attributable to the benzene in cigarette smoke was estimated to range from 15 to 46% using potencies that we derived from the Hayes et al. (24) results (Equation 2); from 19 to 58% using the potencies published by Crump (22) [based on the Pliofilm cohort data (23)]; and from 12 to 36% using our own potency estimates based on the published Pliofilm cohort results (Equation 1). Based on 95% UCL potencies of these linear models, the AF(benzene) ranged from 19 to 12 1%.
The potency for the second-order model (Equation 3) of the Pliofilm data (assuming one death in the lowest exposure group) was 3.9 x 10-7 per cumulative gram squared (95% UCL, 7.8 x 10-7), and resulted in AF(benzene) ranging from 0.05 to 0.29% (95% UCL, 0.08-0.62%). Equation 4, with unconstrained parameters, produced a negative maximum likelihood estimate for PI. Total leukemia. The cumulative lifetime risk (to 75 years of age) of death from any type of leukemia in never-smokers was 0.300% for females and 0.421% for males. For females, the lifetime risks in light and heavy smokers were 0.344 and 0.379%, respectively; for males, lifetime risks were 0.451 and 0.474%, respectively.
Results for all leukemia are shown in Table 5 . The leukemia potencies ranged from 6.6 x 104 to 1.7 x 10-3 per cumulative gram benzene for the linear models (95% UCL, 1.6 x 10-3 to 2.4 x 10-3). Using maximum likelihood potency estimates for the linear models, the AF(benzene) of smokinginduced leukemia deaths was estimated to range from 21 to 48% using the potencies that we estimated from the China cohort results; from 17 to 39% using potencies published by Crump (37, 38) , N-nitrosodi-nbutylamine (30, 39) , and styrene (30, 40) ; benzene is therefore unlikely to be independently responsible for all smoking-induced leukemia. However, based on current knowledge of the leukemogenicity of these compounds and their relative concentrations in tobacco smoke, it seems likely that benzene's contribution is substantial. Thus, in this analysis, dose-response models including a linear term resulted in much more plausible AF(benzene) than the model including a second-order term only.
As in all risk assessments, we made assumptions when necessary. First, we assumed that the potency of benzene inhaled in the occupational setting is equivalent, gram for gram, to the potency of benzene vapor emitted from combusted cigarettes. In both situations, the route of exposure is by inhalation. As air travels into the lung, rapid increases in the cross-sectional area result in a slowing of the air velocity; in addition, rapid increases in the total surface area of the airway walls contribute to extremely efficient heat exchange. The temperature of cigarette smoke therefore decreases rapidly to body temperature once it is inhaled, and potency differences due to temperature are unlikely in these two exposure settings. It is possible, however, that the carcinogenic potency of benzene exposure in the industrial workplace differs from the potency of benzene in complex mixed exposures such as cigarette smoke. The overall effect of these numerous coexposures, some of which may provide potentiating or inhibiting effects on benzene, is difficult to predict. In addition, it may be impossible with current methods to determine any benzene potency difference between these exposure scenarios because of the low exposure levels experienced by smokers and the complexity of the cigarette smoke mixture.
Our second assumption reflects our choice of multiplicative models for potency calculations. These models assume that the effect of a carcinogen is dependent on the background rate of the disease and are appropriate when a carcinogen operates on the same pathway or pathways that produce the background cancer rate (41) . Although researchers have found that benzene-induced leukemia is often preceded by benzeneinduced pancytopenia (1(), the mechanism of benzene-induced leukemia (42) is insufficiently understood to support a causal pathway distinct from the significant background rate of leukemia. The additive models fit by Crump (22) would have produced somewhat lower risk estimates for benzene-induced leukemia and therefore a smaller contribution to smoking-induced leukemia. Our final conclusions, however, would not have been substantially altered, i.e., that linear models give rise to plausible risk estimates.
A third assumption in our extrapolation of potencies from the occupational cohorts was that the studies were substantially free of confounding, misclassification, and other biases. The Pliofilm cohort is well suited to minimize the possible confounding effects of other leukemogens because the industrial process did not involve exposure to other potential carcinogens. Most benzene-exposed workers in the China cohort were also exposed to toluene and xylene. These compounds are not established human carcinogens, although by competing for P450 they may reduce the metabolism rate of benzene, resulting in an underestimation of the benzene potency. Possible bias due to the healthy worker effect has been controlled in our potency calculations for both cohorts: our model for the Pliofilm data adjusted for differences in background rates between workers and the general population, and the China results were based on a comparison with unexposed workers.
In this study, we conducted a sensitivity analysis of the relationship between benzene and AML under different assumptions regarding the untyped leukemia cases in the lowest exposure category presented by Crump (22) . Although Crump With regard to the validity of our results, our linear multiplicative model potencies based on the Pliofilm cohort are somewhat smaller than those of Crump. There are several possible reasons for the differences. Crump used individual data in his analysis, whereas we calculated potencies based on published summary data from the cohort. Crump evaluated several possible lag times between exposure and the development of leukemia; we used the potency that he obtained based on a 5-year lag, but the summary data that were available for our analysis did not incorporate lag times. Finally, we adjusted for the differences in expected mortality between workers and the general population; Crump did not find the a term to be statistically significant and excluded it from his final models.
As noted in "Results," the lifetime risk of AML mortality is slightly higher in light smokers than in heavy smokers. This counterintuitive finding reflects the increased risk to heavy smokers of death from competing causes, such as other cancers and heart disease. Although the AML death rates for each age category are higher for heavy smokers than for light smokers, the lifetime cumulative risk rises less in the later age categories among heavy smokers because of their dramatically higher all-cause death rate. This effect is also observed in our results for all leukemia; however, the cross-over occurs too late to be reflected in a reversal of the lifetime cumulative probabilities of leukemia death.
Another issue is the potential for sex differences in benzene leukemogenicity. In our study, we assumed the same potency for males as for females. Nevertheless, the difference in overall and smoking-induced rates of leukemia led to a lower attributable fraction for females as compared to males. Background rates of leukemia are higher for men than for women. Evidence supporting a sex difference in benzene leukemogenicity includes recent results of physiologically based pharmacokinetic modeling, which show that under the same exposure conditions, women (51, (56) (57) (58) (59) . Future research may therefore identify benzenespecific markers that will allow a direct assessment of the proportion of leukemias attributable to benzene exposure among smokers and nonsmokers.
The attributable fractions calculated in our study, however, seem reasonable and not unrealistically high in light of the other recognized or suspected leukemogenic compounds present in cigarette smoke (including urethane, 1,3-butadiene, radioactive elements, N-nitrosodi-n-butylamine, and styrene). These additional leukemogens may provide synergistic effects as well as independent contributions to smoking-related leukemia mortality. In addition, as-yet unidentified leukemogens, or potentiation by nonleukemogens, may be important in explaining smoking-induced leukemia. Nevertheless, the results presented here for benzene alone provide evidence supporting the use of linear models to extrapolate substantially below occupational exposures. This conclusion is bolstered by evidence of DNA adduct formation by benzene metabolites (51) (52) (53) (54) (55) .
Although we provided UCLs in this paper, U.S. regulatory agencies do not use them when extrapolating from epidemiologic data. The use of maximum likelihood potency estimates may limit the margin of safety.
In conclusion, we estimate that benzene is responsible for 8-48% of smokinginduced leukemia and for 12-58% of smoking-induced AML. The use of cancer mortality data for smokers and never-smokers provides a real-world upper bound for the estimated low-dose carcinogenicity of cigarette smoke constituents and permits an empirical check on the plausibility of risks extrapolated from benzene exposures in industrial settings 10-to 100-fold higher. Our findings show that models with linear terms produce estimates consistent with known smoking-induced risks and with the presence of other leukemogens in mainstream and sidestream smoke.
